The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The drug development process is long and expensive. Regulatory approval is granted following assessment of efficacy and safety, and drugs intended for use in the treatment of type 2 diabetes are also required to demonstrate cardiovascular safety. Once marketing approval has been granted in the UK, an additional step is required prior to a drug's use: cost‐benefit assessment by the Scottish Medicines...
The association between diabetes and cardiovascular disease is now well accepted. For the Arnold Bloom lecture 2016 I described the great improvements in the management of cardiovascular disease that have occurred in the last 20 years in people with diabetes.
Meta‐analysis has shown reductions in microvascular and macrovascular complications with control of blood pressure, but there is still some...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.